Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Summary

To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.

Timeline

Start

2019-03-04

Primary completion

2022-04-21

Completion

2022-04-21

Outcome

Outcome not reported

Stopped (Business): “Amgen re-evaluated the portfolio and decided to discontinue clinical development activities for AMG 420.”

Publications

• Background Rodriguez C, Rodriguez T, Kentos A, Driessen C, Sunami K, Lesokhin AM, Yee AJ, Minella AC, Maraboina R, Upreti VV, Zhou D, Shabooti M, Stieglmaier J, Quach H. BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study. Leuk Lymphoma. 2025 Nov;66(11):2108-2117. doi: 10.1080/10428194.2025.2528115. Epub 2025 Jul 21.

Drugs

Indications